.Pharmacolibrary.Drugs.ATC.R.R03AK12 .Pharmacolibrary.Drugs.ATC.R.R03AK12| name: | SalmeterolAndBudesonide |
| ATC code: | R03AK12 | route: | inhalation |
| n-compartments | 2 |
A fixed-dose combination of salmeterol, a long-acting beta-2 adrenergic agonist (LABA), and budesonide, an inhaled corticosteroid (ICS). This combination is used as a maintenance treatment for asthma and chronic obstructive pulmonary disease (COPD) to reduce inflammation and bronchodilation. It is approved and commonly used today for these indications.
Pharmacokinetic parameters estimated for healthy adult subjects after inhalation based on published data for individual components; no direct published PK model for the fixed-combination inhaler product exists.
Latorre, M, et al., & Paggiaro, P (2015). Differences in the efficacy and safety among inhaled corticosteroids (ICS)/long-acting beta2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): Role of ICS. Pulmonary pharmacology & therapeutics 30 44–50. DOI:10.1016/j.pupt.2014.10.006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25445928
Kim, D, et al., & Lockey, R (2009). Evaluation of combination long-acting beta-2 agonists and inhaled glucocorticosteroids for treatment of asthma. Expert opinion on drug metabolism & toxicology 5(8) 933–940. DOI:10.1517/17425250903127226 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19619072